ライフサイエンスコーパス: therapeutic

1 Bevacizumab was chosen as the antibody-based therapeutic.

2 have emerged as a biotechnological tool and therapeutic.

3 a realistic approach for assessing potential therapeutics.

4 h are utilized in delivery platforms for RNA therapeutics.

5 d may present as a future target for obesity therapeutics.

6 ons in complement research, diagnostics, and therapeutics.

7 dation for the development of aGPCR-targeted therapeutics.

8 of IFNs, suggesting the potential of IFNs as therapeutics.

9 e of ERK5 and the effectiveness of anti-ERK5 therapeutics.

10 acilitate development of microbiota-directed therapeutics.

11 nd in the use of immune checkpoint inhibitor therapeutics.

12 ve strategy for patients receiving Treg cell therapeutics.

13 lth status of patients and their response to therapeutics.

14 nd outcomes have improved little with modern therapeutics.

15 e important for their efficacy and safety as therapeutics.

16 dicating its utility for evaluation of novel therapeutics.

17 ly experience delayed access to unaffordable therapeutics.

18 nals for self-powered health diagnostics and therapeutics.

19 may prove a useful target for new depression therapeutics.

20 able tool for testing potential vaccines and therapeutics.

21 By coupling light to therapeutic action, improved spatial and temporal select

22 ystem pathologies and possessing accentuated therapeutic activity and reduced side effects.

23 nds alter T cell function, we assessed their therapeutic activity in a mouse model of T cell-mediated

24 on with the control group (P >0.05); and the therapeutic activity of melatonin was limited (P >0.05).

25 s (IRDs) are at the focus of current genetic therapeutic advancements.

26 for the development of improved vaccines and therapeutics against IBVs.

27 thromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease

28 endogenous amino acid, offers new hope as a therapeutic agent for refractory TLE.

29 pathogens by controlled chemoattractant and therapeutic agent release.

30 Furans merit consideration as a new class of therapeutic agents for controlling cancer metastasis.

31 entry, with the potential to be developed as therapeutic agents for the treatment and control of Ebol

32 conomical production of sulfated proteins as therapeutic agents in mammalian systems.

33 In this platform trial of therapeutic agents, we randomly assigned hospitalized pa

34 ial properties, and are considered potential therapeutic agents.

35 ivery of molecules, nanoparticles, and other therapeutic agents.

36 e infectious disease therapy using available therapeutic agents.

37 ptidase IV (DPP-4) which limits their use as therapeutic agents.

38 the action of countless natural stimuli and therapeutic agents.

39 development of new diagnostic, prophylactic, therapeutic and curative strategies is critical to addre

40 lities and offers enormous potential in both therapeutic and diagnostic applications.

41 (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in the field of TB elim

42 Cannabis, or marijuana, has potential therapeutic and medicinal properties related to multiple

43 ulation, and may inform novel strategies for therapeutic and preventative interventions.

44 ave implications for the development of both therapeutic and vaccination strategies.

45 idates for clinical development as potential therapeutic and/or prophylactic agents against SARS-CoV-

46 hrough this, we emphasize recent advances in therapeutics and pinpoint disease-associated variants th

47 ficant advancements have been made in cancer therapeutics and treatments, early disease detection and

48 hat may facilitate development of SARS-CoV-2 therapeutics and vaccines.

49 ease models (e.g. stroke), vascular-targeted therapeutics, and hemodynamic data from other imaging mo

50 malizumab, there is currently still only one therapeutic anti-IgE antibody approved for the treatment

51 ashion, e.g., for assessing the stability of therapeutic antibodies.

52 -down proteomics to significantly streamline therapeutic antibody discovery.

53 In addition to therapeutic anticoagulation, probably less than 10% of p

54 and agents amenable to tissue targeting for therapeutic application have been lacking.

55 bufalin and lycorine as drug candidates for therapeutic applications in cardiac fibrosis and diastol

56 It also discusses potential therapeutic applications of targeting the GDF15-GFRAL pa

57 high temperatures and acidic environments of therapeutic applications significantly limiting therapeu

58 te that GalNAc-conjugated PNAs have possible therapeutic applications.

59 inhibition of PME-1 may constitute a viable therapeutic approach for selectively protecting against

60 tion could represent a mechanistically novel therapeutic approach for the treatment of affective and

61 ther bone marrow cells may represent a novel therapeutic approach for treatment of multiple myeloma.

62 targeting memory Th17 cells may be a viable therapeutic approach in the treatment of age-related dry

63 However, this therapeutic approach is often limited by the extent of C

64 sults suggest G-CSFR blockade as a promising therapeutic approach to attenuate renal IRI.

65 (ASOs) mediated exon skipping is a promising therapeutic approach.

66 dentify new therapeutic targets and putative therapeutic approaches aimed at resolving detrimental my

67 Therapeutic approaches aiming to destabilize MYCN protei

68 elapsed disease remains poor, and thus novel therapeutic approaches are needed.

69 thways and they hold the potential for novel therapeutic approaches as well as a deeper understanding

70 and emphasize the potential for personalized therapeutic approaches for slowing clinical progression

71 ntricular tachycardia, and regarding optimal therapeutic approaches.

72 s, and pre- or probiotics might offer better therapeutic approaches.

73 ies (mAb) with the potency of small molecule therapeutics, are one of the fastest growing pharmaceuti

74 cardiovascular disease targets and emerging therapeutic areas, providing differentiated drug molecul

75 ently, there are no FDA-approved vaccines or therapeutics available to combat VEEV infection.

76 introduce DR3 agonistic treatment as a novel therapeutic avenue for treating T2DM.

77 g of sirolimus plus nintedanib might provide therapeutic benefit in patients with HHT.

78 argeting H(2)S to the mitochondria may be of therapeutic benefit in the prevention of endothelial dys

79 While the therapeutic benefit of monoclonal antibodies against inf

80 onally, LSC-Sec and LSC-Exo exhibit superior therapeutic benefits than their counterparts derived fro

81 nities is imperative to expand the available therapeutics beyond anticoagulants and to target both th

82 Previous work has demonstrated that therapeutic blockade of single miRNAs is possible.

83 proved peanut OIT product Palforzia (Aimmune Therapeutics, Brisbane, Calif).

84 Antibodies are widely used as cancer therapeutics, but their current use is limited by the lo

85 al chemists to access a range of fluorinated therapeutic candidates with distinct physicochemical pro

86 Spinal cord injury remains a scientific and therapeutic challenge with great cost to individuals and

87 a reservoir for effector T cells with potent therapeutic characteristics.

88 Thus, the combination of these therapeutic classes is of intense research interest.

89 oach, previously unrecognized biological and therapeutic complexity is emerging.

90 isotope provides a theranostic pair with the therapeutic copper isotope (67)Cu.

91 topical corticosteroids (STC) belong to the therapeutic cornerstones.

92 Advancement of near-term targeted therapeutics could crucially depend on thoughtful design

93 induced coagulopathy (TIC), to support early therapeutic decision-making.

94 tibility testing (AST), resulting in delayed therapeutic decisions at the point of care.

95 wing histo-morphological evaluation dictates therapeutic decisions, where antibiotics are used for H.

96 framework for use of preclinical models for therapeutic development.

97 nd ensuing network robustness has frustrated therapeutic development.

98 ive analysis of COVID-19 related markers for therapeutic, diagnostic, epidemiologic, and prognostic p

99 In contrast with previous therapeutics directly linking Dox and TF, cytotoxicity o

100 ntestinal epithelium, a valuable activity at therapeutic doses on a range of clinical pathogens, medi

101 rate the dual-targeted delivery and enhanced therapeutic effect of eHNP-A1-CD15-LDE225 via scavenger

102 he neural circuit mechanisms underlying this therapeutic effect remain unknown.

103 rapeutic applications significantly limiting therapeutic effectiveness.

104 evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders.

105 his finding leads us to hypothesize that the therapeutic effects of CoQ10, frequently administered to

106 In the current study, we examined the therapeutic effects of Tris DBA on glomerular cell proli

107 To establish proof-of-principle therapeutic effects, we tested PEAMOtecan as monotherapy

108 microneedles (MHMs) while maintaining the MH therapeutic effects.

109 1) plays a significant role in mediating its therapeutic effects.

110 Their therapeutic efficacy and preliminary toxicology profiles

111 s a potential adjunctive approach to improve therapeutic efficacy of SSRI antidepressants.

112 quires T cell migration from lymph nodes for therapeutic efficacy.

113 s and create a modified BoNT/B with improved therapeutic efficacy.

114 Current monoamine transmission modulating therapeutics, even with proper adherence and acceptable

115 Nucleic acids are a promising type of therapeutic for the treatment of a wide range of conditi

116 insights into the future of microbiota-based therapeutics for CDI.

117 arkable process may help the design of novel therapeutics for neurodegeneration and other pathologies

118 e emerged as a class of potentially powerful therapeutics for neurodegenerative CNS diseases.

119 ising avenue to follow in the development of therapeutics for treatment of S. pneumoniae.

120 sequence and uses it as an activator for a "therapeutic" function, namely, the cleavage of another R

121 Therapeutic glucocorticoids have been widely used in rhe

122 etformin in monotherapy does not achieve the therapeutic goals.

123 Therapeutic hypothermia was associated with an increase

124 e striatum and to assess the outcome of deep therapeutic hypothermia.

125 d an HtrA1-blocking Fab fragment to test the therapeutic hypothesis that HtrA1 protease activity is i

126 A significant therapeutic impact on patients with bladder cancer is fo

127 e, as well as discussing the mechanistic and therapeutic implications of these findings in the wider

128 ated DNA damage and execution with potential therapeutic implications.

129 that early blockade of the IL-1 receptor is therapeutic in acute hyperinflammatory respiratory failu

130 lenges associated with administering protein therapeutics, including biotransformation via clipping,

131 the framework for optimization in cell-based therapeutics intended to mitigate cardiomyopathic damage

132 sing systems are promising targets for human therapeutic intervention and developing stress-resilient

133 f early embryogenesis and new strategies for therapeutic intervention in early pregnancy loss.

134 c free thiols are amenable to nutritional or therapeutic intervention.

135 ulation imbalance and identify potential for therapeutic intervention.

136 bility of DS and to evaluate the efficacy of therapeutic interventions for breathing and sleep anomal

137 ce centrally mediated events and on possible therapeutic interventions to correct imbalances in this

138 tant cells, suggesting the potential for new therapeutic interventions, directed against evolving res

139 h SARS-CoV-2, requires urgent development of therapeutic interventions.

140 facilitate closed-loop neurostimulation for therapeutic interventions.

141 enetically edited ex vivo to generate stable therapeutic iTregs.

142 um engine core and inner chemoattractant and therapeutic layers.

143 that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric d

144 vessel in the right arm (10 mg/kg, providing therapeutic-level antibody concentrations), immediately

145 a depot that remains localized and maintains therapeutic levels of sunitinib in retinal pigmented epi

146 of guidelines for clinicians to improve the therapeutic management of patients with both cancer and

147 Though its therapeutic mechanisms remain unclear, it has been sugge

148 may serve as potential targets for potential therapeutic mediation as well as biomarkers of negative

149 monstrations of in vivo imaging, control and therapeutic medical applications of such micro/nanorobot

150 lities observed in patients and suggests new therapeutic modalities.

151 e safety, efficacy and applicability of this therapeutic modality.

152 ch may reveal NMJ targets and pathways whose therapeutic modulation will help slow the progression of

153 al industry for the quantitative analysis of therapeutic molecules.

154 Although therapeutic monoclonal antibodies (mAbs) have demonstrat

155 s that may provide an initial screen for all therapeutic monoclonal antibodies.

156 The most common therapeutic needs involved new drugs (n = 149, 51.0%), c

157 Conclusion: Both diagnostic and therapeutic nuclear medicine procedures declined precipi

158 onin, but they take several weeks to achieve therapeutic onset.

159 those pathways, and their inhibition offers therapeutic opportunities.

160 t protecting Tie2 shedding might offer a new therapeutic opportunity for the treatment of septic vasc

161 Currently, the main therapeutic option for these dysfunctions is neobladder

162 study establishes tipifarnib as a potential therapeutic option in T-cell leukemia and TCL.

163 fering and accepting OIT, respectively, as a therapeutic option.

164 easily achieved by all patients, alternative therapeutic options are currently being evaluated.

165 cular features remain poorly understood, and therapeutic options are limited.

166 lternative" approach, which proposes further therapeutic options for each BCLC-defined stage.

167 Therapeutic options for metastatic UM are limited, with

168 ays are amongst the most commonly prescribed therapeutic options for sinonasal diseases in humans.

169 atients, leading clinicians to explore other therapeutic options such as electroconvulsive therapy, t

170 ficantly to our understanding of AF and some therapeutic options.

171 ic indicator of disease progression and as a therapeutic outcome measure in response to treatment.

172 on of Miltefosine with GM-CSF do not improve therapeutic outcome.

173 can be utilized to improve MSC retention and therapeutic outcome.

174 To improve therapeutic outcomes, we microinjected ASO directly into

175 umor selectivity to achieve improved in vivo therapeutic outcomes.

176 view of TAK1 signaling and provide important therapeutic perspectives related to its function in diff

177 of which are parasite-specific, opens up new therapeutic possibilities.

178 pharmacokinetic properties, indicating their therapeutic potential for the treatment of inflammatory

179 atment-related toxicity that limits the full therapeutic potential in adults.

180 purpose of this study was to investigate the therapeutic potential of activating the aryl hydrocarbon

181 In this study, the therapeutic potential of CH24H inhibition was investigat

182 We investigated the therapeutic potential of IL-4 against fatal malaria in P

183 transcriptional targets in human PH and the therapeutic potential of isoform-selective enzyme modula

184 lic function, which could severely limit the therapeutic potential of targeting Grb14.

185 To better assess the therapeutic potential of their exogenous administration,

186 ed T cell differentiation and underscore the therapeutic potential of transiently inhibiting LDH duri

187 arget several cancer drivers has shown great therapeutic potential.

188 erefore, manipulating this system has strong therapeutic potential.

189 f principle that D/N Vif variants could have therapeutic potential.

190 omaterials has become of interest due to its therapeutic potential.

191 the essential first step in evaluating their therapeutic potential.

192 Community screening and therapeutic prevention strategies may reduce the inciden

193 d striatum may prompt the development of new therapeutic principles for Parkinson's disease.

194 for mitochondrial axonal transport, and the therapeutic promise of TRPV4 antagonists for patients wi

195 We compared therapeutic properties of natural and engineered chemoki

196 he mechanisms underlying n-3 PUFAs potential therapeutic properties remain unknown.

197 prove detection of counterfit and unlicensed therapeutic proteins.

198 Besides, for therapeutic purposes, the effect of these nanoparticles

199 Cell metformin loads in the therapeutic range lowered cell G6P but not ATP and decre

200 In mice, both prophylactic and therapeutic RDV improve pulmonary function and reduce lu

201 breast cancer patients treated with the same therapeutic regimen but who achieved different treatment

202 an islet allograft rejection and developed a therapeutic regimen of low-dose recombinant human interl

203 y structural motifs that can be targeted for therapeutic regulation.

204 t nursing staff to develop and maintain good therapeutic relationships is poor, despite this being a

205 agenda into interventions that support good therapeutic relationships that serve both staff and pati

206 Despite their potential therapeutic relevance, the biosynthesis of serrulatane d

207 tion of signaling kinetics to developing new therapeutics requires reliable kinetic assays and an ana

208 the tumor microenvironment, metastasis, and therapeutic resistance.

209 f performing 3D cell model analysis and cell-therapeutic response studies.

210 type as a biomarker for melanoma outcome and therapeutic response.

211 ent status for targeting the iCP to elicit a therapeutic response.

212 s function to dictate cancer progression and therapeutic response.

213 e genome, is producing important preliminary therapeutic results that could provide new options for c

214 ir future potential for disease modeling and therapeutic screening applications.

215 l of cardiac fibrosis in both preventive and therapeutic settings, as well as in the Dahl salt-sensit

216 red advances in the field beyond the current therapeutic standards, which consist of supportive care

217 infection may lead to the development of new therapeutic strategies against chronic CHIKV disease.

218 Therapeutic strategies and experimental paradigms should

219 m of action for ACVR1 mutations, and suggest therapeutic strategies for DIPGs.

220 euron-cancer interactions will elucidate new therapeutic strategies for these presently lethal brain

221 thogenesis of COVID-19 and discuss potential therapeutic strategies in the management of patients wit

222 nsplantation and NF-kappaB1 pathway-targeted therapeutic strategies should be considered in the futur

223 r the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs.

224 ceptor (RXR) has been proposed as one of the therapeutic strategies to treat individuals with metabol

225 ss of function to develop safe and effective therapeutic strategies.

226 ptoms, but their detection involves specific therapeutic strategies.

227 old age is crucial to develop preventive or therapeutic strategies.

228 ovide preclinical proof of concept for a new therapeutic strategy and address an unmet need for this

229 o supplementation has emerged as a potential therapeutic strategy for managing CKD.

230 t the maternal SNORD116 locus is a potential therapeutic strategy for PWS.

231 nced delivery to develop a clinically viable therapeutic strategy for tumours overexpressing the epid

232 f Bruton tyrosine kinase (BTK), is a leading therapeutic strategy in B-cell malignancies, including c

233 This therapeutic strategy may alter myocardial energy metabol

234 e plasminogen activator receptor (uPAR) as a therapeutic strategy to attenuate acute kidney injury in

235 eration, thereby elucidating a potential new therapeutic strategy to combat AMD.

236 nhibiting DNA damage repair is proposed as a therapeutic strategy to improve outcomes for patients wi

237 roperties, and targeting SHP2 may serve as a therapeutic strategy to overcome tumor resistance to osi

238 logical CatC inhibition could be a potential therapeutic strategy to prevent the irreversible pulmona

239 nclusion, improving autophagic flux may be a therapeutic strategy to protect endothelial function fro

240 on of bacterial function could be a powerful therapeutic strategy.

241 d melanoma cells after surgical removal as a therapeutic strategy.

242 TPCs might represent a novel therapeutic target against HIV-1 infection and HIV-assoc

243 the IUPHAR/BPS Guide to Pharmacology and the Therapeutic Target Database.

244 This enzyme has also emerged as a therapeutic target for cardiovascular disease due to its

245 he inhibition of NETs represents a potential therapeutic target for COVID-19.

246 the system could represent a novel potential therapeutic target for DS.

247 A activity mediated by LC-NE may be a viable therapeutic target for individuals with stress- and trau

248 ed receptor (GPCR) considered as a promising therapeutic target for neuropsychiatric disorders; its p

249 hmatic Th cells, identifying them as a novel therapeutic target for obesity-related asthma, a disease

250 s, cardiac D1R has the potential to become a therapeutic target for preventing heart failure-associat

251 ssed in the brain and represents a promising therapeutic target for the treatment of Huntington's dis

252 cle and hepatic function may represent a new therapeutic target for treating disordered energy metabo

253 A key therapeutic target in PD is alpha-synuclein (alphaS), wh

254 ous results showed that HMGA2 is a potential therapeutic target of anticancer and anti-obesity drugs

255 notherapy and identify ALKBH5 as a potential therapeutic target to enhance immunotherapy outcome in m

256 our results suggest that IL-27 represents a therapeutic target to limit susceptibility and improve i

257 ne and BP and suggest a novel mechanism, and therapeutic target, for aging-induced essential hyperten

258 nfection of host macrophages and a potential therapeutic target.

259 age-related vascular changes and imply that therapeutic targeting of blood vessels may restore aged

260 Therapeutic targeting of epigenetic modulators offers a

261 d DR, there is an urgent need to develop new therapeutics targeting the mitochondria to prevent or re

262 ne germline or somatic aberration, 71.4% had therapeutic targets and 5.2% had a change in diagnosis.

263 Hence, we identify new therapeutic targets and putative therapeutic approaches

264 This provides potential therapeutic targets for the treatment of EBV-associated

265 X3, thus providing additional possible novel therapeutic targets for tumors having deregulated Wnt/be

266 mising diagnostic, prognostic biomarkers and therapeutic targets in breast cancer.

267 ication) pinpoint oncogenic driver genes and therapeutic targets in cancer genomes.

268 To identify new therapeutic targets in CIC-DUX4 sarcoma, we performed ch

269 tform for the discovery of much-needed novel therapeutic targets in this chronic disease.

270 identify the molecular mechanisms and novel therapeutic targets of late-onset Alzheimer's Disease (L

271 ysiology with the potential to unravel novel therapeutic targets.

272 type-selective vulnerability and to identify therapeutic targets.

273 ing the potential value of these proteins as therapeutic targets.

274 DRB1, which might help to identify potential therapeutic targets.

275 receptor kinases (TRKs) are promising cancer therapeutic targets.

276 inflammation and identify several potential therapeutic targets.

277 ring caloric restriction may yield promising therapeutic targets.

278 characterization, damage quantification, and therapeutic techniques that exploit the physical princip

279 throughput and practical preclinical in vivo therapeutic testing.

280 esis of SARS-CoV-2, vaccine development, and therapeutic testing.

281 We designed a novel digital therapeutic that modifies patient-selected cinematic con

282 opment of prebiotic, probiotic, or synthetic therapeutics that decrease the risk of autoimmune, metab

283 elsus (1493-1541) on chemical agents used as therapeutics, "the dose makes the poison," it is now rea

284 ical and clinical studies revealed a limited therapeutic time window and systemic aspects of the dise

285 tiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic

286 monitoring applications, from biosensors to therapeutic treatment agents, their toxicity and their u

287 ersally implemented in clinical research and therapeutic trials.

288 enoxaparin 4,000 international units bid or therapeutic unfractioned heparin).

289 considered for appropriate experimental and therapeutic use of these reagents.

290 sites with immense potential diagnostic and therapeutic utility.

291 le of IL-31 in IBH of horses and developed a therapeutic vaccine against equine IL-31 (eIL-31).

292 ibitors for many distinct protein targets of therapeutic value.

293 potential of Pd nanoparticles to create new therapeutic vectors.

294 selected cinematic content in real-time into therapeutic visual input, while objectively monitoring a

295 ppressor and that KMT2D deficiency confers a therapeutic vulnerability to glycolytic inhibitors.

296 se that measure total cellular uptake of RNA therapeutics, which includes both productive and non-pro

297 These results define a therapeutic window targeting the inflammatory phase for

298 veloped to identify the effects of different therapeutic windows for preclinical brain research.

299 hat could provide new options for cell-based therapeutics with curative intent.

300 e of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins appro